Betta Pharmaceuticals Co., Ltd. announced a private placement by signing subscription agreement of no more than 25,967,281 A shares at an issue price of CNY 38.51 per share for gross proceeds of no more than CNY 1000 million on June 13, 2022. The transaction will include participation from returning investor Ding Lieming, associated relationship with the company. The issue price is not lower than 80% of the company's average stock trading price in the 20 trading days before the pricing benchmark date for this issuance.

The number of shares to be issued not exceeding 30% of the company's total share capital before the issuance. The transaction has been reviewed and approved at the 33rd meeting of the third board of directors of the company, reviewed and approved by the Shenzhen Stock Exchange and approved by the China Securities Regulatory Commission. The share to be issued shall not be transferred within 18 months from the date of the end of the issuance.

The issuance resolution is valid for 12 months from the date when the company's general meeting of shareholders considers and approves the resolution related to the issuance of shares to specific objects.